IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Shareholding for the Period Ended March 31, 2020
IOL Chemicals & Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned subject, please find enclosed herewith a certificate received from M/s. Alankit Assignment Limited, Registrar and Share Transfer Agent of the Company in compliance with the requirements of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2020. Hope you will find the same in order. IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Compliance Certificate For The Half Year Ended 31 March 2020.
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith compliance certificate for the half year ended 31 March 2020. IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abhay Raj SinghDesignation :- Company Secretary and Compliance Officer IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Clarification
With reference to Movement in Price, IOL Chemicals & Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed. IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Clarification sought from IOL Chemicals & Pharmaceuticals Ltd
The Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on April 13th, 2020, with reference to Movement in Price.The reply is awaited. IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Dividend Updates
Update with regard to Payment of Interim Dividend 2019-20 IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Closure of Trading Window
Pursuant to the requirements of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's 'Code of Conduct to Regulate, Monitor and Reporting of Trading by Designated Persons' the Trading Window for dealing in the Securities of the Company, shall remain closed from 01 April 2020 till expiry of 48 hours from the date of audited financial results for quarter and year ended 31 March 2020 are made public. During the closure of Trading Window, Insiders are also advised not to deal in the shares of the Company. The date of the Board Meeting for adoption of above said financial results shall be intimated in due course. This is for information and record please. IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Pre-Payment Of Term Debt
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that, today, the Company has pre-paid Rs 63.93 Crore against balance outstanding Term Loans of the Company. The Company has pre-paid the Term Loan of aggregating Rs 225.37 Crore till date (i.e. Rs 205.32 Crore during the Current FY and Rs 20.05 Crore in Previous FY). As on date, there is no amount outstanding against any Term Loan for the Company. You are requested to kindly take the same on record. IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - EUGMP Certification From National Institute Of Pharmacy And Nutrition, Hungary
Dear Sir, We are pleased to inform the Exchange that National Institute of Pharmacy and Nutrition, Hungary vide its letter no OGYEI/53372-6/2019, dated 16/03/2020 has renewed its EUGMP Certification for Company's products Ibuprofen, Lamotrigine, Metformin Hydrochloride and also approved recently launched products vide this certification and therefore Company's following products are now have EUGMP Certification: 1.Ibuprofen 2.Lamotrigine 3.Metformin Hydrochloride 4.Fenofibrate 5.Clopidogrel Hydrogen Sulfate 6.Pantoprazole Sodium Sesquihydrate With this certification, the Company will have more penetration in European Market for its products.